The Analysis of Reasons for Malignant Skin Tumors Late Diagnosis
Reuf Karabeg, Darko Lukic, Zlata Janjic, Malik Jakirlic, Vanis Dujso, Jadran Bandic, Nenad Babic, Amela Karabeg, Vladimir Guzvic, Predrag Lazic
Mat Soc Med. 2012; 24(2): 73-75
Introduction: Timely diagnosis is a prerequisite for the successful treatment of malignant skin tumors. Late diagnosis leads a patient into a situation of losing valuable time and chance for cure. Material and methods: A prospective study was conducted from February 2006 until August 2011 which analyzed the reasons that led to establishing the diagnosis of malignant skin tumors in 220 patients. Patients were divided into two groups: Group A (102 patients), patients with diagnosed melanoma, and group B (118 patients) of patients suffering from basocellular (BCC) and planocellular cell (PCC) skin cancer. Parameters for comparison of analysis results were the reasons for coming to examination and reasons for not coming to the examination, because of which skin cancers were not diagnosed in time. Goal: To determine the factors that influences the establishment of late diagnosis and treatment of skin tumors. Results: It was confirmed that the prejudices of patients that tumors of the skin „should not be operated because it is dangerous“ is the main reason for late diagnosis. At the same time it is confirmed that the belief that it is unnecessary to operate congenital changes of the skin is the second most important reason for delayed diagnosis of malignant skin tumors.
1. Lukić D, Bandić J, Lazić P. Rana detekcija melanoma, jedino rešenje za izlečenje opake bolesti. Medicinska istraživanja. 2005; 39(1): 48-53.
2. Balch CM, Soong SJ, Atkins MB, Buzaid AC, Cascinelli N, Coit DG et al. An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin. 2004; 54: 131-149.
3. Kalady MF, White RR, Johnson JL, Tyler DS, Steigler HF. Thin melanomas: predictive lethal characteristics from a 30-year clinical experience. Ann Surg. 2003; 238: 528–537.
4. Pawlik TM, Ross MI, Thompson FJ, Eggermont A, Gerschenwald JE. The risk of in-transit melanoma metastases depends on tumor biology and not the surgical approach to regional lymph nodes. J Clin Oncol. 2005; 23: 4588-4590.
5. Kang JC, Wanek LA, Essner R, Faries MB, Foshag LJ, Morton DL. Sentinel lymphadenectomy does not increase the incidence of in-transit metastases in primary melanoma. J Clin Oncol. 2005; 23: 4764-4770.
6. Balch CM, Buzaid AC, Soong SJ et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001; 19: 3635-3648.
7. Andersen BL, Shapiro CL, Farrar WB, Crespin T, Wells-Digregorio S. Psychological responses to cancer recurrence. Cancer. 2005; 104: 1540-1547.
8. McCutcheon B, White K, Kotwall C, Germolic D, Rebolloso Y, Hamann MS et al. A preliminary study of imiquimod treatment in variants of basocellular carcinoma. Am Surg. 2005; 71(8): 662-665.
9. Pennington BE, Leffe DJ. Mohs micrographic surgery: Established uses and emerging trends. Oncology. 2005; 19(9): 1165-1171.
10. Lukić D, Bandić J, Ivić D. Rezultati lečenja planocelularnog i bazocelularnog karcinoma kože glave i vrata i drugih anatomskih regija. Medicinska istraživanja. 2006; 40(1): 29-35.
11. Anwar U, Ghazal AS, Ahmad M, Sharpe DT. Horrifying basocellular carcinoma forearm lesion leading to shoulder disarticulation. Plast Reconstr Surg. 2006; 117-119.
12. Asilian A, Tamizifar B. Aggressive and neglected basocellular carcinoma. Dermatologic Surgery. 2005; 31: 1468-1471.
13. Deo SV, Hazarika S, Shukla NK, Kumar S, Kar M, Samaiya A. Surgical management of skin cancers: Experience from a regional cancer centre in North India. Indian journal of cancer; 2005; 42: 145-150.
14. Eisner JM, Russell M. Cartilage hair hypoplasia and multiple basocellular carcinomas. J Am Acad Dermatol. 2006; 54-58.
15. Hutcheson AC, Fisher AH, Lang PG. Basocellular carcinomas with unusual histologic patterns. Journal of the American Academy of Dermatology. 2005; 53(5): 833.